Beam Therapeutics BEAM
NASDAQ BEAM
$24.43 -0.09 (-0.37%)
At close: Sep 30, 2026 · 4:00 PM EDT

Beam Therapeutics (BEAM) Equity Income (2022)

Updated

Beam Therapeutics (BEAM) recorded Equity Income of $255.15 million in FY2025.

Analysis

Beam Therapeutics (BEAM) Equity Income (2022) Analysis & Trends

  • The FY2025 figure is the lowest annual Equity Income since FY2022.
  • Per Business Quant data, BEAM's Equity Income was -$25.5 million in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Income (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn -
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn -
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn -
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -2.00 Mn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn -10.00 Mn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn -
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Beam Therapeutics 2.53 Bn 2.53 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 -25.50 Mn
API Access

Beam Therapeutics Equity Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=equity-income&ticker=BEAM&period=max&api_key=YOUR_API_KEY